ESR1 and breast carcinoma: However, emerging data suggest that different tumors are likely to respond to DZNep in a heterogenous fashion [35], [36]—for example, estrogen receptor (ER)-negative breast cancers with low BRCA1 levels may be particularly DZNep-sensitive [35].